{
    "ticker": "SUPN",
    "name": "Supernus Pharmaceuticals, Inc.",
    "description": "Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products for the treatment of central nervous system (CNS) diseases. Founded in 2008 and headquartered in Rockville, Maryland, Supernus has established itself as a leader in the CNS space, particularly in the treatment of epilepsy and attention deficit hyperactivity disorder (ADHD). The company markets several approved products, including Oxtellar XR for epilepsy and Trokendi XR for migraine prevention. Supernus is committed to improving the lives of patients through the development of new therapies that address unmet medical needs. With a robust pipeline that includes both novel formulations and new indications, the company aims to expand its reach in the CNS market. Supernus is also dedicated to research and development, investing significantly in its pipeline to explore new treatment options that can enhance patient outcomes. The company\u2019s strategic focus on CNS disorders reflects its understanding of the complexities of these conditions and its commitment to providing effective solutions for patients and healthcare providers alike.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2008",
    "website": "https://www.supernus.com",
    "ceo": "Jack A. Khattar",
    "social_media": {
        "twitter": "https://twitter.com/SupernusPharma",
        "linkedin": "https://www.linkedin.com/company/supernus-pharmaceuticals"
    },
    "investor_relations": "https://investors.supernus.com",
    "key_executives": [
        {
            "name": "Jack A. Khattar",
            "position": "CEO"
        },
        {
            "name": "Gregory S. Patrick",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "CNS Products",
            "products": [
                "Oxtellar XR",
                "Trokendi XR"
            ]
        }
    ],
    "seo": {
        "meta_title": "Supernus Pharmaceuticals, Inc. | Innovative CNS Treatments",
        "meta_description": "Discover Supernus Pharmaceuticals, Inc., a leader in developing innovative treatments for CNS disorders. Learn about their products, mission, and commitment to patient care.",
        "keywords": [
            "Supernus",
            "Pharmaceuticals",
            "CNS Disorders",
            "Epilepsy Treatment",
            "ADHD Treatment",
            "Oxtellar XR",
            "Trokendi XR"
        ]
    },
    "faq": [
        {
            "question": "What does Supernus Pharmaceuticals focus on?",
            "answer": "Supernus Pharmaceuticals focuses on developing treatments for central nervous system disorders, particularly epilepsy and ADHD."
        },
        {
            "question": "Who is the CEO of Supernus Pharmaceuticals?",
            "answer": "Jack A. Khattar is the CEO of Supernus Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Supernus Pharmaceuticals headquartered?",
            "answer": "Supernus Pharmaceuticals is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What are Supernus's main products?",
            "answer": "Supernus's main products include Oxtellar XR for epilepsy and Trokendi XR for migraine prevention."
        },
        {
            "question": "When was Supernus Pharmaceuticals founded?",
            "answer": "Supernus Pharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "NVS",
        "ABBV",
        "PFE"
    ],
    "related_stocks": [
        "JNJ",
        "MRK",
        "AMGN",
        "GILD"
    ]
}